Efficacy of metformin in the treatment of abdominal obesity patients without diabetes.

Efficacy of metformin in the treatment of abdominal obesity patients without diabetes.

PHD Krasnokutskiy S.V., prof. Korzh O.M., PHD Kochuyev G.I. Kharkiv Academy of Postgraduate Education. Department of General Practice, Family Medicine.

Krasnokutskiy SV, Korzh OM, Kochuyev GI. [Efficacy of metformin in the treatment of abdominal obesity patients without diabetes]. Shidnoevr. z. vnutr. simejnoi med. 2015;2:82-84. Russian.
http://dx.doi.org/10.15407/internalmed2015.02.082

Download.PDF

1. Smertnist v Ukraini [Death rate in Ukraine] http://forum.mediaport.ua/read.php?5,278125 http://nbnews.com.ua/ru/tema/99063/. Ukrainian
2. Diabetes Prevention Program Research Group [Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin] N Engl. J Med. 2002; 346: 393—403. English
3. [Metformin diabetes drug could extend lifespan] http://www. medicalnewstoday.com/articles/280725.php. English
4. Pankiv VI. [Pleiotropnye effekty metformina: antionkogennoe deistvie (obzor literatury)]. [Pleotropic effects of metformin: antioncogenic action (literature review)]. Mezhdunarodnyi endokrinologicheskii zhurnal. 2011; 49 (3): 13—15 p. Russian
5. Zhang H, Gao C, Fang L. [Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a metaanalysis ]. Scand. J. Gastroenterol. 2012; (11). English
6. Chen G, Xu S, Renko K, Derwahl M. [Metformin inhibits growth of thyroid carcinoma cells, suppresses self renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents]. J. Clin. Endocrinol. Metab. 2012; 97 (4): 510—520. English
http://dx.doi.org/10.1210/jc.2011-1754
7. http://www.medicalnewstoday.com/articles/277679.php English
8. Kolodzieczyk B, Duleba AJ, Spaczynski RZ, authors. [Fertil Steril]. 2000; 6 (73): 1149-1154. English
9. Pugeat M, Ducluzeau PH, authors. [Drugs.]. 1999; 1:41-6: 75—82. English
10. Seal FG, Robinson RD, Neal GS, authors. [Reprod Med]. 2000; 6 (45): 507-510. English
11. Leo DV, Marca LA, Orvieto R, authors. [Clin Endocrinol Metab]. 2000 Apr; 85(4):1598-1600. English
12. http://www.rmj.ru/articles_6570.htm. Russian
13. Lindstrom J, Tuomilehto J. [The diabetes risk score: a practical tool to predict type 2 diabetes risk]. Diabetes Care. 2003; (26): 725—731. English
http://dx.doi.org/10.2337/diacare.26.3.725
14. Padwal R, Li SK, Lau DC, authors. [Long-term pharmacotherapy for obesity and overweight]. In: Cochrane Database of Systematic Reviews. 2007; 3. English
15. Hubert HB, Feinleib M, McNamara PM, Castelli WP. [Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study]. Circulation. 1983; (67): 968—977. English
http://dx.doi.org/10.1161/01.CIR.67.5.968
16. Mokdad AH, Ford ES, Bowman BA. [Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001]. JAMA. 2003; 289: 76—79. English
http://dx.doi.org/10.1001/jama.289.1.76
17. Diabetes Prevention Program Research Group. [Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin]. N. Engl. J. Med. 2012; (346) 393-403. English
18. Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. [Pharmacological and surgical management of obesity in primary care — a clinical practice guidelines from the American College of Physicians]. Ann. Intern. Med. 2005; 7 (142): 525—531. English
http://dx.doi.org/10.7326/0003-4819-142-7-200504050-00011